Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CFD | P00746 | 1/20 | 0.48 |
| ▸ | TPSB2 | P20231 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3964418 | 0.99 | KMT2A (0.53) | SMN1; SMN2KMT2ACFDTPSB2CYP4F2 | |
| SCHEMBL15137119 | 0.98 | KMT2A (0.54) | SMN1; SMN2KMT2ACFDTPSB2CYP4F2 | |
| SCHEMBL3964184 | 0.94 | KMT2A (0.55) | SMN1; SMN2KMT2ACFDTPSB2CYP4F2 | |
| SCHEMBL3972720 | 0.87 | SMN1; SMN2 (0.69) | SMN1; SMN2KMT2ACFDTPSB2CYP4F2 | |
| SCHEMBL3966532 | 0.85 | KMT2A (0.52) | SMN1; SMN2KMT2ACFDTPSB2CYP4F2 | |
| SCHEMBL29818949 | 0.84 | KMT2A (0.52) | SMN1; SMN2KMT2AMAOBTACR1 | |
| SCHEMBL3972169 | 0.83 | SMN1; SMN2 (0.45) | SMN1; SMN2KMT2ACFDTPSB2KDM4E | |
| SCHEMBL3967162 | 0.81 | ALDH1A1 (0.47) | SMN1; SMN2KMT2ACFDTPSB2KDM4E | |
| SCHEMBL3964690 | 0.81 | CYP1A2 (0.43) | SMN1; SMN2KMT2ACFDTPSB2KDM4E | |
| SCHEMBL3967907 | 0.81 | TSHR (0.52) | SMN1; SMN2KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829244-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20130197096-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2091955-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | Acucela, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197096-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | SMN1; SMN2 42/4885KMT2A 3103/4885CFD 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.